Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

Autor:	Maple Fung, J. Kopicko, C. Storgard, Kenneth G. Saag, Nihar Bhakta, Anne-Kathrin Tausche, Scott Baumgartner, Rieke Alten, Scott Adler, Nicola Dalbeth
Rok vydání:	2017
Předmět:	Adult Male Xanthine Oxidase medicine.medical_specialty Adolescent Gout medicine.drug_class Drug Resistance Pharmacology Placebo Gastroenterology Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Rheumatology Internal medicine medicine Clinical endpoint Humans Pharmacology (medical) 030212 general & internal medicine Enzyme Inhibitors Adverse effect Xanthine oxidase inhibitor Contraindication Aged Aged 80 and over 030203 arthritis & rheumatology business.industry Lesinurad Middle Aged Triazoles Uricosuric Agents medicine.disease Treatment Outcome chemistry Thioglycolates Uric acid Female business
Zdroj:	Rheumatology. 56:2170-2178
ISSN:	1462-0332 1462-0324
DOI:	10.1093/rheumatology/kex350
Popis:	Objective To investigate the efficacy and safety of lesinurad, a selective uric acid reabsorption inhibitor, in a 6 month, phase 3 clinical trial and extension study. Methods Patients with gout who cannot take a xanthine oxidase inhibitor (XOI) and have serum uric acid (sUA) ⩾6.5 mg/dl were randomized to receive oral lesinurad (400 mg daily) or placebo. The primary endpoint was the proportion of patients with sUA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f259315042f81c571e50f1d570fc53e https://doi.org/10.1093/rheumatology/kex350 Zobrazit plný text záznamu